Overview

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Status:
Terminated

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see the effects, good and/or bad, of the drug combination of gemcitabine, docetaxel and pazopanib on sarcoma. This is a phase Ib-phase II clinical trial. The goal of a phase Ib part of the clinical trial is to confirm a dose of the drugs that is safe. The investigators determine this by closely checking for side effects that the patient may experience.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

National Comprehensive Cancer Network
Northwestern University
University of California, Los Angeles
Washington University School of Medicine

Treatments:

Docetaxel
Gemcitabine